Is Novo Nordisk Stock a Buy?
Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...
BioSpace3d
GLP-1 Injectables Will Soon Be Joined by Orals. Is the Industry Ready to Scale?
With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply for ...
Fierce Biotech5d
Novo Nordisk pens $2B deal for triple G agonist tied to 15% weight loss at 12 weeks
Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...
Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped
First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...
TCTMD4h
STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients
While the exact mechanism is unknown, the data suggest a multitude of benefits independent of large weight loss.
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
The issuer is solely responsible for the content of this announcement.
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and ...